| Document |
Document Title |
|
WO/2012/010644A1 |
Process for the synthesis of an isothiocyanate of general formula (I) SCN‑R1-R4-R2 in which R1 and R2 represent, independently of one another, an alkyl, aryl or alkylaryl group, R4 represents a carbonyl, sulphinyl or sulphonyl group or...
|
|
WO/2012/006953A1 |
Disclosed are oxazine derivatives of formula (I) having BACE inhibitory activity, wherein all of the variables are as defined in the specification, in free form or in salt form, their preparation methods, their medical use and medicament...
|
|
WO/2012/008435A1 |
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represente...
|
|
WO/2012/004378A1 |
The present invention relates spiro- cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; -W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof ...
|
|
WO/2012/004375A1 |
The present invention relates to bisaryl (thio)morpholine derivatives of the formula (I) wherein R1 is an aryl substitutent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more s...
|
|
WO/2012/000608A2 |
The present invention relates to novel beta-aminoaldehyde derivatives of the formulae (I), (II) and (III), in which the substituents R1 to R5 and A have the meaning given in the description, to a novel process for their preparation, to i...
|
|
WO/2011/161030A1 |
The invention relates to heterocyclic substituted methoxyphenyl derivatives having an oxo group, and to the physiologically compatible salts thereof. The invention relates to compounds of formula (I), where R1, R2, R3, R4, R10, X, n, B1,...
|
|
WO/2011/161128A1 |
The present invention relates to compounds defined by formula I wherein the variables R1x, R2x, R3x, R4x, R5x, R6x, R7x, RNx, R10x, Ax, Zx and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the c...
|
|
WO/2011/156655A2 |
Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for u...
|
|
WO/2011/154148A1 |
The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal.
|
|
WO/2011/154431A1 |
The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to ...
|
|
WO/2011/154678A1 |
Compounds of formula (I), having activities at muscarinic and β2-receptors (MABAs) for use in therapy.
|
|
WO/2011/154827A2 |
The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can ...
|
|
WO/2011/147279A1 |
Disclosed is a synthesis method of a compound of formula 1, 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-
4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-tr
iazole-3-one (i.e. aprepitant), which comprises cyclisi...
|
|
WO/2011/146821A2 |
The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine...
|
|
WO/2011/146850A1 |
Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, seroton...
|
|
WO/2011/145669A1 |
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...
|
|
WO/2011/137089A1 |
Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of disease...
|
|
WO/2011/136484A1 |
Provided are novel organic electroluminescent compounds and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits high luminous efficiency in blue color and excellent life property, i...
|
|
WO/2011/132712A1 |
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...
|
|
WO/2011/131316A1 |
A process for preparing 4-(4-aminophenyl)morpholin-3-one from 4-(4-nitrophenyl)morpholin-3-one by reducing the nitro group with hydrogen, characterized in that the reaction is effected in water or a mixture of a water-miscible solvent an...
|
|
WO/2011/130194A2 |
Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantiall...
|
|
WO/2011/121068A1 |
The present invention concerns amino derivatives of cyclohex-2-enone of formula (I) and the salts thereof. Said derivatives have proved to be particularly effective as antioxidants in the treatment of cellular oxidative stress, especiall...
|
|
WO/2011/121309A1 |
A compound having the formula (1) wherein W represents N or CH; R1 represents H or C1-3 alkyl; R2 represents a N-containing heterocyclyl ring or a -C1-3 alkylene-N-containing heterocyclyl group; in which any N-containing heterocyclyl com...
|
|
WO/2011/120604A1 |
The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are...
|
|
WO/2011/118672A1 |
Disclosed is a pharmaceutical product, particularly a pharmaceutical composition having a plasma kallikrein inhibition activity and is useful as a prophylactic or therapeutic agent for edemas (particularly hereditary vascular edema and c...
|
|
WO/2011/117254A1 |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.
|
|
WO/2011/107903A1 |
The present invention provides for highly pure mosapride citrate dihydrate and processes for its preparation. The present invention further provides a process for the preparation of mosapride citrate dihydrate substantially free of impur...
|
|
WO/2011/104127A1 |
The invention pertains to a compound generating an acid of the formula (I) or (II), for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes, Formula (I) and Formula (II), wherein X is CH2 or CO; Y...
|
|
WO/2011/105700A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same. Since the organic electroluminescent compounds exhibit high luminous efficiency in blue color, and excellent life proper...
|
|
WO/2011/103435A2 |
Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically...
|
|
WO/2011/098501A1 |
The present invention relates to the use of a compound having the formula (II) for the preparation of a compound having the formula (V). Methods of preparing the compound having the formula (V) using the compound having the formula (II) ...
|
|
WO/2011/093603A1 |
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits good luminous efficiency and excellent life property, it may be used...
|
|
WO/2011/088877A1 |
The present invention relates to compounds according to formula (I), to the use thereof in organic electronic devices, and to organic electronic devices that contain compounds according to formula (I), preferably as hole transport materi...
|
|
WO/2011/077726A1 |
Disclosed is a compound represented by formula (1) (wherein X, R1, R2a, R2b, R3a, R3b, R4a, R4b, ring A, Y, and the dashed line are described in the description), a pharmaceutically acceptable salt thereof, or a solvate of either, as an ...
|
|
WO/2011/079105A1 |
The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are...
|
|
WO/2011/076678A1 |
The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, ha...
|
|
WO/2011/076930A1 |
The present invention concerns cyclic hidroxylamine derivatives of formula (I), and the salts thereof. Said derivatives have proved to be particularly effective as antioxidants for treating cellular oxidative stress, particularly in the ...
|
|
WO/2011/073276A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein E, Z, m, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases...
|
|
WO/2011/073273A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, p, E, X, R1, R2, R3, R4 R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of...
|
|
WO/2011/072345A1 |
The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprisin...
|
|
WO/2011/071136A1 |
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.
|
|
WO/2011/071135A1 |
Disclosed is a compound or the like which serves as a prophylactic or therapeutic agent for diseases induced by the production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound represented by formul...
|
|
WO/2011/072257A2 |
There are provided compounds and methods for the detection of amyloids and treatment of diseases related to amyloids including Alzheimer's disease and other related amyloid-based neurodegenerative diseases.
|
|
WO/2011/071109A1 |
Disclosed is a compound or the like which serves as a prophylactic or therapeutic agent for diseases induced by the production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound represented by formul...
|
|
WO/2011/069934A1 |
The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)- phenyl]-amide derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing the...
|
|
WO/2011/070029A1 |
This invention relates to 5,6-dihydro-4H-[1,3]oxazin-2-ylamine compounds of the formula (I) wherein R1 to R5 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are B...
|
|
WO/2011/067306A1 |
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a p...
|
|
WO/2011/064897A1 |
Disclosed is a bis-benzoxazinone compound which has high purity without substantially containing an alkali metal salt and forms a resin composition having excellent hydrolysis resistance when the compound is incorporated in a resin. The ...
|
|
WO/2011/066394A1 |
The present invention is directed towards a new class of semi-conducting nonacene derivatives. These compounds are all soluble species and they all possess superior resistance to oxidation as compared to their counterparts that lack the ...
|
